Literature DB >> 1679338

An evaluation of the partial dopamine agonist terguride regarding positive symptoms reduction in schizophrenics.

R Olbrich1, H Schanz.   

Abstract

Eleven schizophrenics (7 females) displaying an acute psychotic episode received the partial dopamine agonist terguride in doses up to 2 mg per day. Improvement in terms of positive symptoms reduction was observed in two cases only. In contrast, in a previous clinical trial targeted at negative schizophrenic symptoms, the majority of the patients appeared to have benefited from terguride application.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1679338     DOI： 10.1007/bf01244973

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  3 in total

1.  The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics.

Authors:  R Olbrich; H Schanz
Journal:  Pharmacopsychiatry       Date:  1988-11       Impact factor: 5.788

2.  Dual action on central dopamine function of transdihydrolisuride, a 9, 10-dihydrogenated analogue of the ergot dopamine agonist lisuride.

Authors:  H Wachtel; R Dorow
Journal:  Life Sci       Date:  1983-01-24       Impact factor: 5.037

3.  Dopamine receptor agonists: intrinsic activity vs. state of receptor.

Authors:  A Carlsson
Journal:  J Neural Transm       Date:  1983       Impact factor: 3.575
  3 in total
  5 in total

1.  II. In vitro evidence that (-)-OSU6162 and (+)-OSU6162 produce their behavioral effects through 5-HT2A serotonin and D2 dopamine receptors.

Authors:  Ethan S Burstein; Maria L Carlsson; Michelle Owens; Jian-Nong Ma; Hans H Schiffer; Arvid Carlsson; Uli Hacksell
Journal:  J Neural Transm (Vienna)       Date:  2011-08-25       Impact factor: 3.575

Review 2.  α2-Adrenoceptors are targets for antipsychotic drugs.

Authors:  Jan Brosda; Florian Jantschak; Heinz H Pertz
Journal:  Psychopharmacology (Berl)       Date:  2014-02-02       Impact factor: 4.530

Review 3.  Efficacy and safety of aripiprazole in child and adolescent patients.

Authors:  Eiji Kirino
Journal:  Eur Child Adolesc Psychiatry       Date:  2012-03-25       Impact factor: 4.785

Review 4.  Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.

Authors:  Eiji Kirino
Journal:  Adolesc Health Med Ther       Date:  2014-11-27

Review 5.  Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism.

Authors:  Andrea de Bartolomeis; Carmine Tomasetti; Felice Iasevoli
Journal:  CNS Drugs       Date:  2015-09       Impact factor: 5.749
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.